[go: up one dir, main page]

MX2021014345A - Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. - Google Patents

Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.

Info

Publication number
MX2021014345A
MX2021014345A MX2021014345A MX2021014345A MX2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
therapeutic applications
compounds targeting
targeting proteins
protein
Prior art date
Application number
MX2021014345A
Other languages
English (en)
Inventor
Eduardo Torres
Kyle W H Chan
Paul E Erdman
Leah Fung
David Aaron Hecht
Aparajita Hoskote Chourasia
Imelda Lam
Frank Mercurio
Robert Sullivan
Original Assignee
Biotheryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheryx Inc filed Critical Biotheryx Inc
Publication of MX2021014345A publication Critical patent/MX2021014345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente descripción provee compuestos, por ejemplo, un compuesto de Fórmula (I), que modula la función de una proteína y/o restaura la homeostasis de la proteína. La descripción provee un método para modular una enfermedad, trastorno, afección o respuesta mediada por proteínas. Se proveen composiciones, incluso en combinación con otros agentes terapéuticos.
MX2021014345A 2019-05-24 2020-05-22 Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. MX2021014345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852844P 2019-05-24 2019-05-24
PCT/US2020/034264 WO2020242960A1 (en) 2019-05-24 2020-05-22 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications

Publications (1)

Publication Number Publication Date
MX2021014345A true MX2021014345A (es) 2022-01-06

Family

ID=71092611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014345A MX2021014345A (es) 2019-05-24 2020-05-22 Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.

Country Status (14)

Country Link
US (2) US11345712B2 (es)
EP (1) EP3976623A1 (es)
JP (1) JP2022533260A (es)
KR (1) KR20220023343A (es)
CN (1) CN114502543A (es)
AU (1) AU2020283744A1 (es)
CA (1) CA3140078C (es)
EA (1) EA202192910A1 (es)
IL (1) IL288204A (es)
MX (1) MX2021014345A (es)
SG (1) SG11202112355VA (es)
TW (1) TW202110818A (es)
WO (1) WO2020242960A1 (es)
ZA (1) ZA202109124B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
BR112022010019A2 (pt) * 2019-12-06 2022-08-16 Celgene Corp Processos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CA3161497A1 (en) * 2019-12-12 2021-06-17 Kyle W.H. Chan Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
TW202227427A (zh) 2020-09-16 2022-07-16 美商拜歐斯瑞克斯公司 Sos1蛋白降解劑、其醫藥組合物及其治療應用
US20240050428A1 (en) * 2020-10-07 2024-02-15 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
KR20230157936A (ko) 2020-12-14 2023-11-17 바이오테릭스, 인코포레이티드 Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
EP4320125A1 (en) * 2021-04-05 2024-02-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
WO2023274246A1 (zh) * 2021-06-28 2023-01-05 成都分迪药业有限公司 酰胺类化合物及其用途
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023070120A1 (en) * 2021-10-22 2023-04-27 Biotheryx, Inc. Ketoamides for treating malignancy
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
AU2022419982A1 (en) * 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
US20240158370A1 (en) * 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024167423A1 (en) * 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
CN118496213A (zh) * 2023-04-28 2024-08-16 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ES2832475T3 (es) * 2016-01-08 2021-06-10 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
US10406165B2 (en) 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
EP3830093A1 (en) * 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators

Also Published As

Publication number Publication date
JP2022533260A (ja) 2022-07-21
ZA202109124B (en) 2023-10-25
US11345712B2 (en) 2022-05-31
TW202110818A (zh) 2021-03-16
IL288204A (en) 2022-01-01
US20200369679A1 (en) 2020-11-26
AU2020283744A1 (en) 2021-12-09
US20220298172A1 (en) 2022-09-22
CN114502543A (zh) 2022-05-13
CA3140078A1 (en) 2020-12-03
SG11202112355VA (en) 2021-12-30
WO2020242960A1 (en) 2020-12-03
EA202192910A1 (ru) 2022-03-18
EP3976623A1 (en) 2022-04-06
KR20220023343A (ko) 2022-03-02
CA3140078C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
PH12021500014A1 (en) Fused ring compounds
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020003190A (es) Degradadores de proteinas y usos de los mismos.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MY191030A (en) Gdf15 fusion proteins and uses thereof
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2018015353A (es) Usos terapeuticos de un inhibidor de c-raf.
MX2020007628A (es) Composiciones y metodos de uso.
AU2016210835A8 (en) Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
WO2019051327A3 (en) BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
WO2020022898A3 (en) Off-the-shelf cancer vaccines
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
WO2020127376A3 (en) Polypeptides
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение